Welcome to University of Mumbai, Department of Biophysics


Bioinformatics Database on
"Radiosensitisers and Radioprotectors"

Alphabetical Search   >  O   >  ON01210.Na                                                                                                                                                                 Top

ON01210.Na

Go To:


General Features                  Clinical Study                  Chemical Intervention                 Pharmacological Aspects                 
Radiobiological Aspects                  Biological Models                  Biological Target                  Toxicity                 


GENERAL FEATURES

Name: ON01210.Na
Synonyms: Recilisib Sodium[1]
Trade name: Novonex/Ex-Rad®, developed by Onconova Therapeutics and the U.S. Department of Defense[2],[3]
Chemical name: 4-carboxystyrl-4-chlorobenzylsulfone[3]
(E)-4-carboxystyryl-4-chlorobenzylsulfone, sodium salt[4]
Molecular Weight: 358.77 g/mol[5]
Source:
Structure: [2],[6],[5],[7]
Chemical Nature: benzyl sulfone analog[3]
soluble in water, stable at pH 7.6[3]
Actions
& Indications:
Pharmcological Action-
Therapeutic indications:
Preclinical study-
Notes:
REFERENCES
1. Recilisib - Adisinsight, Drug Profile by Onconova Therapeutics.
http://adisinsight.springer.com/drugs/800020974
2. Chun AW et al, Effects of formulation and route of administration on the systemic availability of Ex-RAD®, a new radioprotectant, in preclinical species. Biopharm Drug Dispos. 2011;32(2):99-111.
http://dx.doi.org/10.1002/bdd.741
3. Alfieri AA et al, Radiation damage protection by the benzyl styrl sulfone analog, ex-rad. Int J Radiat Oncol Biol Phys 2004;60(1, Supplement):S367–S368.
http://dx.doi.org/10.1016/j.ijrobp.2004.07.216
4. Fernandes PP, Maniar M, Dash AK, Development and validation of a sensitive liquid chromatographic method for the analysis of a novel radioprotectant: ON 01210.Na. J Pharm Biomed Anal. 2007 ;43(5):1796-803.
http://dx.doi.org/10.1016/j.jpba.2006.11.036
5. Tamhane M et al, Disposition of ON 01210.Na (Ex-RAD®), a novel radioprotectant, in the isolated perfused rat liver: probing metabolic inhibition to increase systemic exposure. Journal of Pharmaceutical Sciences 2013;102(2):732–740.
http://dx.doi.org/10.1002/jps.23391
6. Chun AW et al, Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent. Cancer Chemother Pharmacol. 2009;65(1):177-86.
http://dx.doi.org/10.1007/s00280-009-1022-9
7. Ghosh SP et al, Radiation Protection by a New Chemical Entity, Ex-Rad™: Efficacy and Mechanisms. Radiation Research 2009;171(2):173-179.
http://www.jstor.org/stable/40212747